Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 59% Improvement Relative Risk Recovery 61% Clinical improvement 64% Discharge 56% c19early.com/mf Wong et al. Metformin for COVID-19 Prophylaxis Favors metformin Favors control
Wong, 1,214 patient metformin prophylaxis study: 59% lower mortality [p=0.01], 61% improved recovery [p=0.005], 64% better improvement [p=0.009], and 56% higher hospital discharge [p=0.009] https://c19p.org/wong
copied to clipboard
Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort
Wong et al., Frontiers in Endocrinology, doi:10.3389/fendo.2022.810914
7 Mar 2022    Source   PDF   Share   Tweet
Retrospective 1,214 COVID+ type 2 diabetes patients in Hong Kong, showing lower mortality and improved recovery with metformin use.
risk of death, 59.0% lower, OR 0.41, p = 0.01, treatment 786, control 428, adjusted per study, propensity score weighting, multivariable, RR approximated with OR.
risk of no recovery, 60.6% lower, OR 0.39, p = 0.005, treatment 786, control 428, adjusted per study, inverted to make OR<1 favor treatment, propensity score weighting, multivariable, RR approximated with OR.
clinical improvement, 63.5% better, OR 0.36, p = 0.009, treatment 786, control 428, adjusted per study, inverted to make OR<1 favor treatment, propensity score weighting, multivariable, RR approximated with OR.
risk of no hospital discharge, 55.8% lower, OR 0.44, p = 0.009, treatment 786, control 428, adjusted per study, inverted to make OR<1 favor treatment, propensity score weighting, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wong et al., 7 Mar 2022, retrospective, China, peer-reviewed, 11 authors, study period 21 January, 2020 - 31 January, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit